Design Therapeutics, Inc. (DSGN) vs Geron Corporation (GERN)

Design Therapeutics, Inc. and Geron Corporation are both Biotechnology companies. Design Therapeutics, Inc. and Geron Corporation are of similar size ($815.9M and $809.3M). Design Therapeutics, Inc. has the higher net margin (0.00% vs −33.1%) and the higher return on invested capital (0.00% vs −89.9%). Across the 16 metrics below, Design Therapeutics, Inc. leads on 9 and Geron Corporation on 7.

Valuation

Metric DSGN GERN Biotechnology median
P/E n/m n/m 7.88
P/S 3,363.10 4.13 11.47
P/B 3.77 3.87 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 2,445.42 3.59 10.73
Earnings yield (9.70%) (8.37%) (28.84%)
Free cash flow yield (7.27%) (13.58%) (23.03%)

Profitability

Metric DSGN GERN Biotechnology median
Gross margin 0.00% 93.51% 65.16%
Operating margin 0.00% (25.31%) 0.00%
Net margin 0.00% (33.05%) 0.00%
Free cash flow margin 0.00% (56.10%) 0.00%
Return on equity (34.13%) (28.28%) (57.72%)
Return on assets (32.33%) (12.59%) (49.22%)
Return on invested capital 0.00% (89.85%) 0.00%

Growth

Metric DSGN GERN Biotechnology median
Revenue growth (TTM) — 24.39% 5.64%
EPS growth (last fiscal year) (38.64%) 51.85% —
Revenue growth, 5-year CAGR — 273.49% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric DSGN GERN Biotechnology median
Debt to equity 0.00 0.55 0.00
Current ratio 18.86 6.92 4.73
Net debt to EBITDA 2.68 3.28 0.96

Dividend

Metric DSGN GERN Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric DSGN GERN Biotechnology median
Market cap 809.26m 815.94m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack